Viewing Study NCT05253651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:39 PM
Ignite Modification Date: 2025-12-25 @ 9:29 PM
Study NCT ID: NCT05253651
Status: RECRUITING
Last Update Posted: 2025-12-17
First Post: 2022-02-14
Is NOT Gene Therapy: False
Has Adverse Events: False
Brief Title: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Colorectal Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Colorectal Cancer View
None CRC View
None Seattle Genetics View